Place of immunomodulators in the treatment of pelvic inflammatory diseases
| Autor: | I V Kuznetsova, T N Rashidov |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Гинекология, Vol 18, Iss 5, Pp 26-31 (2016) |
| Druh dokumentu: | article |
| ISSN: | 2079-5696 2079-5831 |
| Popis: | Pelvic inflammatory diseases (PID) are widespread in the population of women of reproductive age. The special properties of pathogens of urogenital infections, immune dysfunction of host systems often lead to the formation of chronic inflammation, especially in women with asymptomatic infection infections, sexually transmitted infections, and patients with subclinical PID. Chronic pelvic inflammatory disease, in turn, are associated with numerous disorders reproductive system, including infertility, miscarriage, chronic pelvic pain. Prevention of chronic inflammation and its negative consequences is early detection and adequate treatment as STDs and PID, especially their subclinical variants. Unfortunately, antibiotics do not always justify the hopes placed in it, partly because of rising resistance of pathogens, in part due to their own side effects, including an immunosuppressive action. To optimize antibiotic therapy and prevention of pelvic inflammatory disease and relapse in the treatment regimen immunomodulators may be used. Since a key role in the immune response to infectious implementation is played by phagocytic link, inclusion in therapy azoximer bromide, providing a full function of phagocytes, seems reasonable and appropriate. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|